Oncolytics Biotech, Inc.
ONCY
Get informed when a big investor buys or sells
+ FollowMarket Cap$55.9M
Close$
$0.05
91.5% downside
Current Fair Value
91.5% downsideOvervalued by 91.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $55.90 Million |
|---|---|
| Enterprise Value | $52.23 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.41 |
| Beta | 1.16 |
| Outstanding Shares | 119,739,942 |
Return
| Return on Equity | 560.92% |
|---|---|
| Return on Assets | -450.95% |
| Return on Invested Capital | -1420.73% |
Valuation & Multiples
| P/E Ratio | -2.31 |
|---|---|
| PEG | -4.34 |
| Price to Sales | - |
| Price to Book Ratio | -0.55 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.5 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | -0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.05
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 30, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.23%▼ 3.31% |
|---|---|
| Total Invested | $183,952▼ 95.12% |
| Investors Holding | 4▼ 74.00% |
ESG Score
No data